PT Kalbe Genexine Biologics

The hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with prog

Chinese pharma companies are now taking some of their principal products to the smaller global markets of Southeast Asia, which a number are targeting in an expansion push. Hong Kong- and Shanghai-lis

Hong Kong-listed Shanghai Henlius Biotech Co. Ltd. is set to renew Chinese biotechs’ efforts to land an immuno-oncology antibody onto the US market, with a regulatory pathway now set for its anti-PD

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genexine, KGBio Ink $1.1bn License Pact